{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:01:18Z","timestamp":1794632478889,"version":"4.9.1"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Most criteria for genetic testing for prostate cancer susceptibility require a prior diagnosis of prostate cancer, in particular cases with metastatic disease are selected. Advances in the field are expected to improve outcomes through tailored treatments for men with advanced prostate cancer with germline pathogenic variants, although these are not currently offered in the curative setting. A better understanding of the value of genetic testing for prostate cancer susceptibility in screening, for early detection and prevention is necessary. We review and summarize the literature describing germline pathogenic variants in genes associated with increased prostate cancer risk and aggressivity. Important questions include: what is our ability to screen for and prevent prostate cancer in a man with a germline pathogenic variant and how does knowledge of a germline pathogenic variant influence treatment of men with nonmetastatic disease, with hormone-resistant disease and with metastatic disease? The frequency of germline pathogenic variants in prostate cancer is well described, according to personal and family history of cancer and by stage and grade of disease. The role of these genes in aggressive prostate cancer is also discussed. It is timely to consider whether or not genetic testing should be offered to all men with prostate cancer. The goals of testing are to facilitate screening for early cancers in unaffected high-risk men and to prevent advanced disease in men with cancer.<\/jats:p>","DOI":"10.1038\/s41698-022-00282-8","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T10:02:33Z","timestamp":1655892153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["An appraisal of genetic testing for prostate cancer susceptibility"],"prefix":"10.1038","volume":"6","author":[{"given":"Amy","family":"Finch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7987-375X","authenticated-orcid":false,"given":"Roderick","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Vesprini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8177-2429","authenticated-orcid":false,"given":"Justin","family":"Lorentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Thain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad R.","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Cybulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5798-0626","authenticated-orcid":false,"given":"Steven A.","family":"Narod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"282_CR1","unstructured":"National Cancer Institute, Surveillance Epidemiology and End Results Program: Cancer Stat Facts: Prostate Cancer. (2020)."},{"key":"282_CR2","first-page":"2312","volume":"123","author":"A Tsodikov","year":"2017","unstructured":"Tsodikov, A. et al. Is prostate. Cancer Differ. black men.? Answ. 3 Nat. Hist. models Cancer 123, 2312\u20132319 (2017).","journal-title":"Cancer Differ. black men.? Answ. 3 Nat. Hist. models Cancer"},{"key":"282_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ijc.11466","volume":"107","author":"DW Bruner","year":"2003","unstructured":"Bruner, D. W., Moore, D., Parlanti, A., Dorgan, J. & Engstrom, P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J. Cancer 107, 797\u2013803 (2003).","journal-title":"Int J. Cancer"},{"key":"282_CR4","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/jnci\/86.21.1600","volume":"86","author":"DE Goldgar","year":"1994","unstructured":"Goldgar, D. E., Easton, D. F., Cannon-Albright, L. A. & Skolnick, M. H. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J. Natl Cancer Inst. 86, 1600\u20131608 (1994).","journal-title":"J. Natl Cancer Inst."},{"key":"282_CR5","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1093\/hmg\/ddh072","volume":"13","author":"DJ Schaid","year":"2004","unstructured":"Schaid, D. J. The complex genetic epidemiology of prostate cancer. Hum. Mol. Genet 13, R103\u2013R121 (2004).","journal-title":"Hum. Mol. Genet"},{"key":"282_CR6","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41588-018-0142-8","volume":"50","author":"FR Schumacher","year":"2018","unstructured":"Schumacher, F. R. et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat. Genet 50, 928\u2013936 (2018).","journal-title":"Nat. Genet"},{"key":"282_CR7","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2016.69.4935","volume":"35","author":"J Lecarpentier","year":"2017","unstructured":"Lecarpentier, J. et al. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J. Clin. Oncol. 35, 2240\u20132250 (2017).","journal-title":"J. Clin. Oncol."},{"key":"282_CR8","unstructured":"Barnes, D. R. et al. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. J. Natl. Cancer Inst. 114, djab147 (2021)."},{"key":"282_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1158\/1055-9965.EPI-14-0317","volume":"24","author":"A Amin Al Olama","year":"2015","unstructured":"Amin Al Olama, A. et al. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiol. Biomark. Prev. 24, 1121\u20131129 (2015).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"282_CR10","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1086\/316907","volume":"67","author":"A Liede","year":"2000","unstructured":"Liede, A. et al. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am. J. Hum. Genet 67, 1494\u20131504 (2000).","journal-title":"Am. J. Hum. Genet"},{"key":"282_CR11","unstructured":"NCCN. Clinical Practice Guidelines in Oncology, Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V2.2021."},{"key":"282_CR12","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1185\/030079907X219526","volume":"23","author":"J van Adelsberg","year":"2007","unstructured":"van Adelsberg, J. et al. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr. Med Res Opin. 23, 2063\u20132070 (2007).","journal-title":"Curr. Med Res Opin."},{"key":"282_CR13","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1001\/jama.2011.1437","volume":"306","author":"EA Klein","year":"2011","unstructured":"Klein, E. A. et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 306, 1549\u20131556 (2011).","journal-title":"JAMA"},{"key":"282_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1215932","volume":"369","author":"IM Thompson","year":"2013","unstructured":"Thompson, I. M. et al. Long-term survival of participants in the prostate cancer prevention trial. N. Engl. J. Med 369, 603\u2013610 (2013).","journal-title":"N. Engl. J. Med"},{"key":"282_CR15","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","volume":"362","author":"GL Andriole","year":"2010","unstructured":"Andriole, G. L. et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med 362, 1192\u20131202 (2010).","journal-title":"N. Engl. J. Med"},{"key":"282_CR16","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med 360, 1320\u20131328 (2009).","journal-title":"N. Engl. J. Med"},{"key":"282_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","volume":"52","author":"J Hugosson","year":"2018","unstructured":"Hugosson, J. et al. Eighteen-year follow-up of the G\u00f6teborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand. J. Urol. 52, 27\u201337 (2018).","journal-title":"Scand. J. Urol."},{"key":"282_CR18","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.30474","volume":"123","author":"PF Pinsky","year":"2017","unstructured":"Pinsky, P. F. et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 123, 592\u2013599 (2017).","journal-title":"Cancer"},{"key":"282_CR19","unstructured":"USPSTF. U. S. Preventive Services Task Force: Final Recomendation Statement: Prostate Cancer Screening. (2018)."},{"key":"282_CR20","unstructured":"NCCN. Clinical Practice Guidelines in Oncology, Prostate Cancer Early Detection V1.2021."},{"key":"282_CR21","unstructured":"ACS. American Cancer Society Recommendations for Prostate Cancer Early Detection, https:\/\/tinyurl.com\/374wh3h4 (2021)."},{"key":"282_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","volume":"76","author":"EC Page","year":"2019","unstructured":"Page, E. C. et al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur. Urol. 76, 831\u2013842 (2019).","journal-title":"Eur. Urol."},{"key":"282_CR23","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","volume":"31","author":"N Segal","year":"2020","unstructured":"Segal, N. et al. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening. Ann. Oncol. 31, 1545\u20131552 (2020).","journal-title":"Ann. Oncol."},{"key":"282_CR24","doi-asserted-by":"crossref","unstructured":"Woko\u0142orczyk, D. et al. PALB2 mutations and prostate cancer risk and survival. Br. J. Cancer 125, 569\u2013575 (2021).","DOI":"10.1038\/s41416-021-01410-0"},{"key":"282_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/jnci\/djaa132","volume":"113","author":"BF Darst","year":"2021","unstructured":"Darst, B. F. et al. Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. J. Natl Cancer Inst. 113, 616\u2013625 (2021).","journal-title":"J. Natl Cancer Inst."},{"key":"282_CR26","unstructured":"CCS. Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2018. Toronto, ON: Canadian Cancer Society; 2018. Available at: cancer.ca\/Canadian-Cancer-Statistics-2018-EN (accessed [date])."},{"key":"282_CR27","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","volume":"69","author":"DA Siegel","year":"2020","unstructured":"Siegel, D. A., O\u2019Neil, M. E., Richards, T. B., Dowling, N. F. & Weir, H. K. Prostate Cancer Incidence and Survival, by Stage and Race\/Ethnicity - United States, 2001-2017. MMWR Morb. Mortal. Wkly Rep. 69, 1473\u20131480 (2020).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"282_CR28","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","volume":"75","author":"HB Carter","year":"2019","unstructured":"Carter, H. B. et al. Germline Mutations in ATM and BRCA1\/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. Eur. Urol. 75, 743\u2013749 (2019).","journal-title":"Eur. Urol."},{"key":"282_CR29","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro, E. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol. 31, 1748\u20131757 (2013).","journal-title":"J. Clin. Oncol."},{"key":"282_CR30","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.20.00046","volume":"38","author":"VN Giri","year":"2020","unstructured":"Giri, V. N. et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J. Clin. Oncol. 38, 2798\u20132811 (2020).","journal-title":"J. Clin. Oncol."},{"key":"282_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","volume":"68","author":"E Castro","year":"2015","unstructured":"Castro, E. et al. Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Eur. Urol. 68, 186\u2013193 (2015).","journal-title":"Eur. Urol."},{"key":"282_CR32","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0360-3016(01)02684-0","volume":"52","author":"CM Iannuzzi","year":"2002","unstructured":"Iannuzzi, C. M., Atencio, D. P., Green, S., Stock, R. G. & Rosenstein, B. S. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J. Radiat. Oncol. Biol. Phys. 52, 606\u2013613 (2002).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"282_CR33","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijrobp.2004.09.031","volume":"61","author":"JA Cesaretti","year":"2005","unstructured":"Cesaretti, J. A. et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J. Radiat. Oncol. Biol. Phys. 61, 196\u2013202 (2005).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"282_CR34","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.ijrobp.2019.07.026","volume":"105","author":"C Bergom","year":"2019","unstructured":"Bergom, C. et al. The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists. Int J. Radiat. Oncol. Biol. Phys. 105, 698\u2013712 (2019).","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"282_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5489\/cuaj.2806","volume":"9","author":"C Morash","year":"2015","unstructured":"Morash, C. et al. Active surveillance for the management of localized prostate cancer: Guideline recommendations. Can. Urol. Assoc. J. 9, 171\u2013178 (2015).","journal-title":"Can. Urol. Assoc. J."},{"key":"282_CR36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2014.55.1192","volume":"33","author":"L Klotz","year":"2015","unstructured":"Klotz, L. et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J. Clin. Oncol. 33, 272\u2013277 (2015).","journal-title":"J. Clin. Oncol."},{"key":"282_CR37","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","volume":"70","author":"LP Bokhorst","year":"2016","unstructured":"Bokhorst, L. P. et al. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. Eur. Urol. 70, 954\u2013960 (2016).","journal-title":"Eur. Urol."},{"key":"282_CR38","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0094-0143(05)70163-4","volume":"28","author":"M Han","year":"2001","unstructured":"Han, M., Partin, A. W., Pound, C. R., Epstein, J. I. & Walsh, P. C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol. Clin. North Am. 28, 555\u2013565 (2001).","journal-title":"Urol. Clin. North Am."},{"key":"282_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.urology.2004.05.019","volume":"64","author":"CM Gonzalez","year":"2004","unstructured":"Gonzalez, C. M. et al. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. Urology 64, 723\u2013728 (2004).","journal-title":"Urology"},{"key":"282_CR40","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/S0022-5347(01)69079-7","volume":"167","author":"GW Hull","year":"2002","unstructured":"Hull, G. W. et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J. Urol. 167, 528\u2013534 (2002).","journal-title":"J. Urol."},{"key":"282_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S0022-5347(05)67457-5","volume":"164","author":"CL Amling","year":"2000","unstructured":"Amling, C. L. et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J. Urol. 164, 101\u2013105 (2000).","journal-title":"J. Urol."},{"key":"282_CR42","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound, C. R. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591\u20131597 (1999).","journal-title":"JAMA"},{"key":"282_CR43","unstructured":"Tutt, A. N. J. et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N. Engl. J. Med. 384, 2394\u20132405 (2021)."},{"key":"282_CR44","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby, M., Hirst, C. & Crawford, E. D. Characterising the castration-resistant prostate cancer population: a systematic review. Int J. Clin. Pr. 65, 1180\u20131192 (2011).","journal-title":"Int J. Clin. Pr."},{"key":"282_CR45","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","volume":"8","author":"M Annala","year":"2018","unstructured":"Annala, M. et al. Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer. Cancer Disco. 8, 444\u2013457 (2018).","journal-title":"Cancer Disco."},{"key":"282_CR46","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"E Castro","year":"2019","unstructured":"Castro, E. et al. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. J. Clin. Oncol. 37, 490\u2013503 (2019).","journal-title":"J. Clin. Oncol."},{"key":"282_CR47","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.eururo.2018.12.042","volume":"75","author":"G Vandekerkhove","year":"2019","unstructured":"Vandekerkhove, G. et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur. Urol. 75, 667\u2013675 (2019).","journal-title":"Eur. Urol."},{"key":"282_CR48","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41416-020-01114-x","volume":"124","author":"R Lozano","year":"2021","unstructured":"Lozano, R. et al. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br. J. Cancer 124, 552\u2013563 (2021).","journal-title":"Br. J. Cancer"},{"key":"282_CR49","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono, J. et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N. Engl. J. Med."},{"key":"282_CR50","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Abida","year":"2020","unstructured":"Abida, W. et al. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a. J. Clin. Oncol. 38, 3763\u20133772 (2020).","journal-title":"J. Clin. Oncol."},{"key":"282_CR51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","volume":"5","author":"W Abida","year":"2019","unstructured":"Abida, W. et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 5, 471\u2013478 (2019).","journal-title":"JAMA Oncol."},{"key":"282_CR52","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","volume":"343","author":"D Ford","year":"1994","unstructured":"Ford, D., Easton, D. F., Bishop, D. T., Narod, S. A. & Goldgar, D. E. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 343, 692\u2013695 (1994).","journal-title":"Lancet"},{"key":"282_CR53","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1086\/346094","volume":"72","author":"X Dong","year":"2003","unstructured":"Dong, X. et al. Mutations in CHEK2 associated with prostate cancer risk. Am. J. Hum. Genet. 72, 270\u2013280 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"282_CR54","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/sj.bjc.6601425","volume":"89","author":"EH Sepp\u00e4l\u00e4","year":"2003","unstructured":"Sepp\u00e4l\u00e4, E. H. et al. CHEK2 variants associate with hereditary prostate cancer. Br. J. Cancer 89, 1966\u20131970 (2003).","journal-title":"Br. J. Cancer"},{"key":"282_CR55","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/sj.bjc.6602007","volume":"91","author":"S Ang\u00e8le","year":"2004","unstructured":"Ang\u00e8le, S. et al. ATM polymorphisms as risk factors for prostate cancer development. Br. J. Cancer 91, 783\u2013787 (2004).","journal-title":"Br. J. Cancer"},{"key":"282_CR56","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N. Engl. J. Med 375, 443\u2013453 (2016).","journal-title":"N. Engl. J. Med"},{"key":"282_CR57","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1158\/1055-9965.EPI-09-0058","volume":"18","author":"EM Grindedal","year":"2009","unstructured":"Grindedal, E. M. et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol. Biomark. Prev. 18, 2460\u20132467 (2009).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"282_CR58","unstructured":"Lee, D. J. et al. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. Eur Urol. 18, 559\u2013567 (2021)."},{"key":"282_CR59","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/bjc.2014.30","volume":"110","author":"D Leongamornlert","year":"2014","unstructured":"Leongamornlert, D. et al. Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br. J. Cancer 110, 1663\u20131672 (2014).","journal-title":"Br. J. Cancer"},{"key":"282_CR60","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"CGAR Network","year":"2015","unstructured":"Network, C. G. A. R. The Molecular Taxonomy of Primary Prostate Cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"282_CR61","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","volume":"71","author":"R Na","year":"2017","unstructured":"Na, R. et al. Germline Mutations in ATM and BRCA1\/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur. Urol. 71, 740\u2013747 (2017).","journal-title":"Eur. Urol."},{"key":"282_CR62","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","volume":"5","author":"P Nicolosi","year":"2019","unstructured":"Nicolosi, P. et al. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 5, 523\u2013528 (2019).","journal-title":"JAMA Oncol."},{"key":"282_CR63","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1200\/JCO.2004.05.055","volume":"22","author":"A Liede","year":"2004","unstructured":"Liede, A., Karlan, B. Y. & Narod, S. A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J. Clin. Oncol. 22, 735\u2013742 (2004).","journal-title":"J. Clin. Oncol."},{"key":"282_CR64","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/jnci\/94.18.1358","volume":"94","author":"D Thompson","year":"2002","unstructured":"Thompson, D. & Easton, D. F., Breast Cancer Linkage, C. Cancer Incidence in BRCA1 mutation carriers. J. Natl Cancer Inst. 94, 1358\u20131365 (2002).","journal-title":"J. Natl Cancer Inst."},{"key":"282_CR65","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1038\/bjc.2012.146","volume":"106","author":"D Leongamornlert","year":"2012","unstructured":"Leongamornlert, D. et al. Germline BRCA1 mutations increase prostate cancer risk. Br. J. Cancer 106, 1697\u20131701 (2012).","journal-title":"Br. J. Cancer"},{"key":"282_CR66","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","volume":"77","author":"T Nyberg","year":"2020","unstructured":"Nyberg, T. et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur. Urol. 77, 24\u201335 (2020).","journal-title":"Eur. Urol."},{"key":"282_CR67","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker, K. B. et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 317, 2402\u20132416 (2017).","journal-title":"JAMA"},{"key":"282_CR68","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/91.15.1310","volume":"91","author":"BCL Consortium","year":"1999","unstructured":"Consortium, B. C. L. Cancer risks in BRCA2 mutation carriers. J. Natl Cancer Inst. 91, 1310\u20131316 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"282_CR69","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1038\/bjc.2011.383","volume":"105","author":"Z Kote-Jarai","year":"2011","unstructured":"Kote-Jarai, Z. et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br. J. Cancer 105, 1230\u20131234 (2011).","journal-title":"Br. J. Cancer"},{"key":"282_CR70","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/sj.bjc.6604132","volume":"98","author":"A Mitra","year":"2008","unstructured":"Mitra, A. et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br. J. Cancer 98, 502\u2013507 (2008).","journal-title":"Br. J. Cancer"},{"key":"282_CR71","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/jnci\/djm005","volume":"99","author":"L Tryggvad\u00f3ttir","year":"2007","unstructured":"Tryggvad\u00f3ttir, L. et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J. Natl Cancer Inst. 99, 929\u2013935 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"282_CR72","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1038\/bjc.2014.428","volume":"111","author":"MR Akbari","year":"2014","unstructured":"Akbari, M. R. et al. The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. Br. J. Cancer 111, 1238\u20131240 (2014).","journal-title":"Br. J. Cancer"},{"key":"282_CR73","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJM198705213162101","volume":"316","author":"M Swift","year":"1987","unstructured":"Swift, M., Reitnauer, P. J., Morrell, D. & Chase, C. L. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med 316, 1289\u20131294 (1987).","journal-title":"N. Engl. J. Med"},{"key":"282_CR74","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.3747\/co.25.3707","volume":"25","author":"KJ Jerzak","year":"2018","unstructured":"Jerzak, K. J., Mancuso, T. & Eisen, A. Ataxia-telangiectasia gene. Curr. Oncol. 25, e176\u2013e180 (2018).","journal-title":"Curr. Oncol."},{"key":"282_CR75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/cge.12710","volume":"90","author":"NJ van Os","year":"2016","unstructured":"van Os, N. J. et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin. Genet 90, 105\u2013117 (2016).","journal-title":"Clin. Genet"},{"key":"282_CR76","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.eururo.2020.09.002","volume":"79","author":"BF Darst","year":"2021","unstructured":"Darst, B. F. Findings from a Genetic Sequencing Investigation of Men with Familial and Aggressive Prostate Cancer. Eur. Urol. 79, 362\u2013363 (2021).","journal-title":"Eur. Urol."},{"key":"282_CR77","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/ijc.33272","volume":"147","author":"D Woko\u0142orczyk","year":"2020","unstructured":"Woko\u0142orczyk, D. et al. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland. Int J. Cancer 147, 2793\u20132800 (2020).","journal-title":"Int J. Cancer"},{"key":"282_CR78","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling, L. et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N. Engl. J. Med 384, 428\u2013439 (2021).","journal-title":"N. Engl. J. Med"},{"key":"282_CR79","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu, C. et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N. Engl. J. Med 384, 440\u2013451 (2021).","journal-title":"N. Engl. J. Med"},{"key":"282_CR80","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","volume":"29","author":"C Cybulski","year":"2011","unstructured":"Cybulski, C. et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J. Clin. Oncol. 29, 3747\u20133752 (2011).","journal-title":"J. Clin. Oncol."},{"key":"282_CR81","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ijc.29426","volume":"137","author":"M Sio\u0142ek","year":"2015","unstructured":"Sio\u0142ek, M. et al. CHEK2 mutations and the risk of papillary thyroid cancer. Int J. Cancer 137, 548\u2013552 (2015).","journal-title":"Int J. Cancer"},{"key":"282_CR82","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-008-0162-7","volume":"116","author":"M Wasielewski","year":"2009","unstructured":"Wasielewski, M. et al. CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat. 116, 397\u2013400 (2009).","journal-title":"Breast Cancer Res Treat."},{"key":"282_CR83","doi-asserted-by":"publisher","first-page":"294575","DOI":"10.1155\/2014\/294575","volume":"2014","author":"V Hale","year":"2014","unstructured":"Hale, V., Weischer, M. & Park, J. Y. CHEK2 (\u2217) 1100delC Mutation and Risk of Prostate Cancer. Prostate Cancer 2014, 294575 (2014).","journal-title":"Prostate Cancer"},{"key":"282_CR84","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/bjc.2012.486","volume":"108","author":"C Cybulski","year":"2013","unstructured":"Cybulski, C. et al. An inherited NBN mutation is associated with poor prognosis prostate cancer. Br. J. Cancer 108, 461\u2013468 (2013).","journal-title":"Br. J. Cancer"},{"key":"282_CR85","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou, A. C. et al. Breast-cancer risk in families with mutations in PALB2. N. Engl. J. Med 371, 497\u2013506 (2014).","journal-title":"N. Engl. J. Med"},{"key":"282_CR86","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J. Clin. Oncol. 38, 674\u2013685 (2020).","journal-title":"J. Clin. Oncol."},{"key":"282_CR87","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S2468-1253(18)30079-7","volume":"3","author":"E Fewings","year":"2018","unstructured":"Fewings, E. et al. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. Lancet Gastroenterol. Hepatol. 3, 489\u2013498 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"282_CR88","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2018.03.039","volume":"173","author":"KL Huang","year":"2018","unstructured":"Huang, K. L. et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell 173, 355\u2013370.e314 (2018).","journal-title":"Cell"},{"key":"282_CR89","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/j.1399-0004.2008.01125.x","volume":"75","author":"E Barrow","year":"2009","unstructured":"Barrow, E. et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin. Genet 75, 141\u2013149 (2009).","journal-title":"Clin. Genet"},{"key":"282_CR90","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","volume":"36","author":"SW Ten Broeke","year":"2018","unstructured":"Ten Broeke, S. W. et al. Cancer Risks for PMS2-Associated Lynch Syndrome. J. Clin. Oncol. 36, 2961\u20132968 (2018).","journal-title":"J. Clin. Oncol."},{"key":"282_CR91","doi-asserted-by":"crossref","unstructured":"M\u00f8ller, P. et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 67, 1306\u20131316 (2018).","DOI":"10.1136\/gutjnl-2017-314057"},{"key":"282_CR92","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1001\/jama.2011.743","volume":"305","author":"V Bonadona","year":"2011","unstructured":"Bonadona, V. et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 305, 2304\u20132310 (2011).","journal-title":"JAMA"},{"key":"282_CR93","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","volume":"31","author":"VM Raymond","year":"2013","unstructured":"Raymond, V. M. et al. Elevated risk of prostate cancer among men with Lynch syndrome. J. Clin. Oncol. 31, 1713\u20131718 (2013).","journal-title":"J. Clin. Oncol."},{"key":"282_CR94","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","volume":"22","author":"M Dominguez-Valentin","year":"2020","unstructured":"Dominguez-Valentin, M. et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med 22, 15\u201325 (2020).","journal-title":"Genet Med"},{"key":"282_CR95","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1200\/JCO.2012.43.2278","volume":"30","author":"C Engel","year":"2012","unstructured":"Engel, C. et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J. Clin. Oncol. 30, 4409\u20134415 (2012).","journal-title":"J. Clin. Oncol."},{"key":"282_CR96","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1158\/1055-9965.EPI-13-1165","volume":"23","author":"S Ryan","year":"2014","unstructured":"Ryan, S., Jenkins, M. A. & Win, A. K. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol. Biomark. Prev. 23, 437\u2013449 (2014).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"282_CR97","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1093\/annonc\/mdv004","volume":"26","author":"Z Kote-Jarai","year":"2015","unstructured":"Kote-Jarai, Z. et al. Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann. Oncol. 26, 756\u2013761 (2015).","journal-title":"Ann. Oncol."},{"key":"282_CR98","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/jnci\/djs288","volume":"104","author":"MR Akbari","year":"2012","unstructured":"Akbari, M. R. et al. Association between germline HOXB13 G84E mutation and risk of prostate cancer. J. Natl Cancer Inst. 104, 1260\u20131262 (2012).","journal-title":"J. Natl Cancer Inst."},{"key":"282_CR99","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00439-012-1229-4","volume":"132","author":"J Xu","year":"2013","unstructured":"Xu, J. et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum. Genet 132, 5\u201314 (2013).","journal-title":"Hum. Genet"},{"key":"282_CR100","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1158\/1055-9965.EPI-12-1000-T","volume":"22","author":"VH Laitinen","year":"2013","unstructured":"Laitinen, V. H. et al. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol. Biomark. Prev. 22, 452\u2013460 (2013).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"282_CR101","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2018.11.015","volume":"75","author":"T Nyberg","year":"2019","unstructured":"Nyberg, T. et al. Homeobox B13 G84E Mutation and Prostate Cancer Risk. Eur. Urol. 75, 834\u2013845 (2019).","journal-title":"Eur. Urol."},{"key":"282_CR102","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/pros.22594","volume":"73","author":"W Klu\u017aniak","year":"2013","unstructured":"Klu\u017aniak, W. et al. The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate 73, 542\u2013548 (2013).","journal-title":"Prostate"},{"key":"282_CR103","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1110000","volume":"366","author":"CM Ewing","year":"2012","unstructured":"Ewing, C. M. et al. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl. J. Med 366, 141\u2013149 (2012).","journal-title":"N. Engl. J. Med"},{"key":"282_CR104","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/carcin\/bgt055","volume":"34","author":"Z Chen","year":"2013","unstructured":"Chen, Z. et al. The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. Carcinogenesis 34, 1260\u20131264 (2013).","journal-title":"Carcinogenesis"},{"key":"282_CR105","unstructured":"NCCN. Clinical Practice Guidelines in Oncology, Genetic\/Familial High-Risk Assessment: Colorectal V1. 2021."},{"key":"282_CR106","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/jmedgenet-2018-105472","volume":"55","author":"JM McCuaig","year":"2018","unstructured":"McCuaig, J. M. et al. Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. J. Med Genet 55, 571\u2013577 (2018).","journal-title":"J. Med Genet"},{"key":"282_CR107","doi-asserted-by":"crossref","unstructured":"Narod, S. A. et al. The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada. Cancers (Basel) 13, 1894 (2021).","DOI":"10.3390\/cancers13081894"},{"key":"282_CR108","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3747\/co.25.3818","volume":"25","author":"J Lorentz","year":"2018","unstructured":"Lorentz, J., Liu, S. K. & Vesprini, D. Male Oncology Research and Education program for men at high risk for prostate cancer. Curr. Oncol. 25, 170\u2013175 (2018).","journal-title":"Curr. Oncol."},{"key":"282_CR109","doi-asserted-by":"publisher","first-page":"e0186043","DOI":"10.1371\/journal.pone.0186043","volume":"12","author":"P Harter","year":"2017","unstructured":"Harter, P. et al. Prevalence of deleterious germline variants in risk genes including BRCA1\/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One 12, e0186043 (2017).","journal-title":"PLoS One"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00282-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T08:05:10Z","timestamp":1669363510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-022-00282-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":109,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1038\/s41698-022-00282-8","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"6 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Neil Fleshner has received consulting fees from Amgen, Janssen, Astellas, Bayer, Sanofi, Abbvie, Ferring, has stock holdings in POINT Biopharma and Verity pharmaceuticals and is the Chief Medical Officer for Verity pharmaceuticals and POINT Biopharma. Dr. Fleshner holds research grants (paid to the institution) from Janssen, Astellas, Bayer, Sanofi, Nucleix, Progenix, SpectraCure AB, Bavarian Nordic. Dr. Mohammad Akbari holds stock and other ownership interests in Genewise Inc. All other authors have no competing interests to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43"}}